Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials
Autor: | Myat Min Han, Thura Win Htut, Kyaw Zin Thein |
---|---|
Rok vydání: | 2021 |
Předmět: | |
Zdroj: | Journal of Immunotherapy and Precision Oncology. 5:43-47 |
ISSN: | 2590-017X 2666-2345 |
Popis: | Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia. Patients on acalabrutinib experienced higher risk of any-grade cardiac events (risk ratio, 1.75; p = 0.01) while there was a considerable trend toward statistical significance in the risk of any-grade atrial fibrillation (risk ratio, 2.56; p = 0.05). There was no significant increase in the risk of hypertension or high-grade cardiac events or atrial fibrillation in the acalabrutinib group. |
Databáze: | OpenAIRE |
Externí odkaz: |